A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Protein C Activity : 1777
MessagePlease submit a separate, frozen vial for each special coagulation assay ordered.
Test Code
PRTCAC or 1777
Alias/See Also
Protein C Functional, Functional Protein C
CPT Codes
85303
Instructions
Draw blood in light blue-top tube containing 3.2% sodium citrate, mix gently by inverting 3-4 times. Tube must be filled to within +/-10% of fill line.
Platelet-poor plasma: Centrifuge 15 minutes at 1500 g within 1 hour of collection. Using a plastic pipette, remove plasma, taking care to avoid the WBC/platelet buffy layer and place into a plastic vial. Centrifuge a second time and transfer platelet-poor plasma into a new plastic vial. Freeze immediately and ship on dry ice.
Platelet-poor plasma: Centrifuge 15 minutes at 1500 g within 1 hour of collection. Using a plastic pipette, remove plasma, taking care to avoid the WBC/platelet buffy layer and place into a plastic vial. Centrifuge a second time and transfer platelet-poor plasma into a new plastic vial. Freeze immediately and ship on dry ice.
Transport Container
Preferred Specimen
1 mL frozen platelet-poor plasma collected in 3.2% sodium citrate (light blue-top) tube
Minimum Volume
0.5 mL
1 mL frozen platelet-poor plasma collected in 3.2% sodium citrate (light blue-top) tube
Minimum Volume
0.5 mL
Transport Temperature
Frozen.
Specimen Stability
Room temperature: Unacceptable; Refrigerated: Unacceptable; Frozen: 14 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Hemolysis, Received thawed, Received room temperature, Received refrigerated
Methodology
Clotting
Setup Schedule
Tuesday & Thursday
Report Available
1-6 days
Reference Range
70-180 % normal
Clinical Significance
Protein C (PC) deficiency may be congenital or acquired and is associated with venous thrombosis. Acquired PC deficiency may occur with vitamin K antagonists/deficiency, liver disease, malignancy, consumptive DIC, surgery, trauma, and hepatic immaturity of the newborn.
Expected impact by therapeutic levels (potential interference depends upon drug concentration):
1) Vitamin K antagonists (e.g., warfarin): decrease
2) Heparin (UFH or LMWH): no effect to falsely increased activity levels at higher concentrations
3) Dabigatran or Argatroban (thrombin inhibitors): may falsely increase activity
4) Rivaroxaban, Apixaban, Edoxaban (Factor Xa inhibitors): may falsely increase activity
Expected impact by therapeutic levels (potential interference depends upon drug concentration):
1) Vitamin K antagonists (e.g., warfarin): decrease
2) Heparin (UFH or LMWH): no effect to falsely increased activity levels at higher concentrations
3) Dabigatran or Argatroban (thrombin inhibitors): may falsely increase activity
4) Rivaroxaban, Apixaban, Edoxaban (Factor Xa inhibitors): may falsely increase activity
Performing Laboratory
med fusion